Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
Department of Health Sciences Research, Mayo Clinic Minnesota, Rochester, MN 55905, USA.
Alzheimers Res Ther. 2014 Jul 1;6(4):39. doi: 10.1186/alzrt268. eCollection 2014.
MAPT encodes for tau, the predominant component of neurofibrillary tangles that are neuropathological hallmarks of Alzheimer's disease (AD). Genetic association of MAPT variants with late-onset AD (LOAD) risk has been inconsistent, although insufficient power and incomplete assessment of MAPT haplotypes may account for this.
We examined the association of MAPT haplotypes with LOAD risk in more than 20,000 subjects (n-cases = 9,814, n-controls = 11,550) from Mayo Clinic (n-cases = 2,052, n-controls = 3,406) and the Alzheimer's Disease Genetics Consortium (ADGC, n-cases = 7,762, n-controls = 8,144). We also assessed associations with brain MAPT gene expression levels measured in the cerebellum (n = 197) and temporal cortex (n = 202) of LOAD subjects. Six single nucleotide polymorphisms (SNPs) which tag MAPT haplotypes with frequencies greater than 1% were evaluated.
H2-haplotype tagging rs8070723-G allele associated with reduced risk of LOAD (odds ratio, OR = 0.90, 95% confidence interval, CI = 0.85-0.95, p = 5.2E-05) with consistent results in the Mayo (OR = 0.81, p = 7.0E-04) and ADGC (OR = 0.89, p = 1.26E-04) cohorts. rs3785883-A allele was also nominally significantly associated with LOAD risk (OR = 1.06, 95% CI = 1.01-1.13, p = 0.034). Haplotype analysis revealed significant global association with LOAD risk in the combined cohort (p = 0.033), with significant association of the H2 haplotype with reduced risk of LOAD as expected (p = 1.53E-04) and suggestive association with additional haplotypes. MAPT SNPs and haplotypes also associated with brain MAPT levels in the cerebellum and temporal cortex of AD subjects with the strongest associations observed for the H2 haplotype and reduced brain MAPT levels (β = -0.16 to -0.20, p = 1.0E-03 to 3.0E-03).
These results confirm the previously reported MAPT H2 associations with LOAD risk in two large series, that this haplotype has the strongest effect on brain MAPT expression amongst those tested and identify additional haplotypes with suggestive associations, which require replication in independent series. These biologically congruent results provide compelling evidence to screen the MAPT region for regulatory variants which confer LOAD risk by influencing its brain gene expression.
MAPT 编码了微管相关蛋白 tau,它是阿尔茨海默病(AD)神经病理学特征神经纤维缠结的主要成分。MAPT 变异与迟发性 AD(LOAD)风险的遗传关联一直不一致,尽管可能由于效力不足和 MAPT 单倍型评估不完整而导致这种情况。
我们在超过 20000 名来自梅奥诊所(n 病例= 9814,n 对照= 11550)和阿尔茨海默病遗传学联合会(ADGC,n 病例= 7762,n 对照= 8144)的受试者中检查了 MAPT 单倍型与 LOAD 风险的关联。我们还评估了与 LOAD 受试者小脑(n=197)和颞皮质(n=202)中 MAPT 基因表达水平的关联。评估了频率大于 1%的六个单核苷酸多态性(SNP)标记 MAPT 单倍型。
H2 单倍型标记 rs8070723-G 等位基因与 LOAD 风险降低相关(优势比,OR=0.90,95%置信区间,CI=0.85-0.95,p=5.2E-05),在梅奥(OR=0.81,p=7.0E-04)和 ADGC 队列中得到一致的结果。rs3785883-A 等位基因也与 LOAD 风险呈名义显著相关(OR=1.06,95%CI=1.01-1.13,p=0.034)。单倍型分析显示在合并队列中与 LOAD 风险有显著的整体关联(p=0.033),H2 单倍型与 LOAD 风险降低的关联如预期的那样显著(p=1.53E-04),并且与其他单倍型有提示性关联。MAPT SNPs 和单倍型也与 AD 受试者的小脑和颞皮质中的脑 MAPT 水平相关,在 H2 单倍型和降低的脑 MAPT 水平方面观察到最强的关联(β=-0.16 至-0.20,p=1.0E-03 至 3.0E-03)。
这些结果证实了先前在两个大型系列中报道的 MAPT H2 与 LOAD 风险的关联,该单倍型对测试的脑 MAPT 表达具有最强的影响,并确定了其他具有提示性关联的单倍型,这些关联需要在独立系列中进行复制。这些具有生物学一致性的结果为筛选 MAPT 区域提供了令人信服的证据,该区域通过影响其脑基因表达来赋予 LOAD 风险。